» Articles » PMID: 29658779

Fully Closed-Loop Multiple Model Probabilistic Predictive Controller Artificial Pancreas Performance in Adolescents and Adults in a Supervised Hotel Setting

Abstract

Background: Initial Food and Drug Administration-approved artificial pancreas (AP) systems will be hybrid closed-loop systems that require prandial meal announcements and will not eliminate the burden of premeal insulin dosing. Multiple model probabilistic predictive control (MMPPC) is a fully closed-loop system that uses probabilistic estimation of meals to allow for automated meal detection. In this study, we describe the safety and performance of the MMPPC system with announced and unannounced meals in a supervised hotel setting.

Research Design And Methods: The Android phone-based AP system with remote monitoring was tested for 72 h in six adults and four adolescents across three clinical sites with daily exercise and meal challenges involving both three announced (manual bolus by patient) and six unannounced (no bolus by patient) meals. Safety criteria were predefined. Controller aggressiveness was adapted daily based on prior hypoglycemic events.

Results: Mean 24-h continuous glucose monitor (CGM) was 157.4 ± 14.4 mg/dL, with 63.6 ± 9.2% of readings between 70 and 180 mg/dL, 2.9 ± 2.3% of readings <70 mg/dL, and 9.0 ± 3.9% of readings >250 mg/dL. Moderate hyperglycemia was relatively common with 24.6 ± 6.2% of readings between 180 and 250 mg/dL, primarily within 3 h after a meal. Overnight mean CGM was 139.6 ± 27.6 mg/dL, with 77.9 ± 16.4% between 70 and 180 mg/dL, 3.0 ± 4.5% <70 mg/dL, 17.1 ± 14.9% between 180 and 250 mg/dL, and 2.0 ± 4.5%> 250 mg/dL. Postprandial hyperglycemia was more common for unannounced meals compared with announced meals (4-h postmeal CGM 197.8 ± 44.1 vs. 140.6 ± 35.0 mg/dL; P < 0.001). No participants met safety stopping criteria.

Conclusions: MMPPC was safe in a supervised setting despite meal and exercise challenges. Further studies are needed in a less supervised environment.

Citing Articles

First validity testing of GluciQuizz, a French self-questionnaire evaluating carb-counting for patients with type 1 diabetes.

Tatulashvili S, Dreves B, Cosson E, Meyer L, Morello R, Joubert M PLoS One. 2025; 20(2):e0318746.

PMID: 39999057 PMC: 11856297. DOI: 10.1371/journal.pone.0318746.


The DERMIS Study: Methodologies, Results, and Implications for the Future.

Hirsch I, Khakpour D, Joseph J, Shinohara M, Wang R, Klueh U J Diabetes Sci Technol. 2024; 19322968241298005.

PMID: 39633523 PMC: 11618839. DOI: 10.1177/19322968241298005.


Use of diabetes technology in children.

Schoelwer M, DeBoer M, Breton M Diabetologia. 2024; 67(10):2075-2084.

PMID: 38995398 PMC: 11457698. DOI: 10.1007/s00125-024-06218-0.


Multivariable Automated Insulin Delivery System for Handling Planned and Spontaneous Physical Activities.

Askari M, Ahmadasas M, Shahidehpour A, Rashid M, Quinn L, Park M J Diabetes Sci Technol. 2023; 17(6):1456-1469.

PMID: 37908123 PMC: 10658686. DOI: 10.1177/19322968231204884.


MiniMed 780G™ advanced hybrid closed-loop system performance in Egyptian patients with type 1 diabetes across different age groups: evidence from real-world users.

Elbarbary N, Rahman Ismail E Diabetol Metab Syndr. 2023; 15(1):205.

PMID: 37845757 PMC: 10580510. DOI: 10.1186/s13098-023-01184-w.


References
1.
Forlenza G, Buckingham B, Maahs D . Progress in Diabetes Technology: Developments in Insulin Pumps, Continuous Glucose Monitors, and Progress towards the Artificial Pancreas. J Pediatr. 2015; 169:13-20. PMC: 6214345. DOI: 10.1016/j.jpeds.2015.10.015. View

2.
Miller K, Foster N, Beck R, Bergenstal R, DuBose S, DiMeglio L . Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015; 38(6):971-8. DOI: 10.2337/dc15-0078. View

3.
Chernavvsky D, DeBoer M, Keith-Hynes P, Mize B, McElwee M, Demartini S . Use of an artificial pancreas among adolescents for a missed snack bolus and an underestimated meal bolus. Pediatr Diabetes. 2014; 17(1):28-35. DOI: 10.1111/pedi.12230. View

4.
Blauw H, van Bon A, Koops R, DeVries J . Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home. Diabetes Obes Metab. 2016; 18(7):671-7. PMC: 5111773. DOI: 10.1111/dom.12663. View

5.
van Bon A, Luijf Y, Koebrugge R, Koops R, Hoekstra J, DeVries J . Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. Diabetes Technol Ther. 2013; 16(3):131-6. PMC: 3934514. DOI: 10.1089/dia.2013.0166. View